Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
Competition for resources is growing, and the usual supply chain partners may not have available capacity in the preferred timeframe.
Last week, HHS Secretary Alex Azar assumed all final authority in deciding new rules regarding food, medical devices and new medications.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
Cidara Therapeutics is hoping that its novel approach to influenza will prevent future “twindemic” double threats like the one we may face this year.